Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.374, Iss.2, 2006-11, pp. : 79-85

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Darifenacin: a novel M₃ muscarinic selective receptor antagonist for the treatment of overactive bladder

By Chapple Christopher R

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1493-1500

Informa Healthcare

Access to resources Recommend Favorite

Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer's Disease

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3353-3361

Bentham Science Publishers

Access to resources Recommend Favorite

Inhaled Muscarinic Acetylcholine Receptor Antagonists for Treatment of COPD

Current Medicinal Chemistry, Vol. 20, Iss. 12, 2013-06 ,pp. : 1464-1476

Bentham Science Publishers

Access to resources Recommend Favorite

Solifenacin in Overactive Bladder Syndrome

By Payne Christopher K.

Drugs, Vol. 66, Iss. 2, 2006-01 ,pp. : 175-190

Adis International

Access to resources Recommend Favorite

Solifenacin in Overactive Bladder Syndrome

By Simpson Dene Wagstaff Antona J.

Drugs & Aging, Vol. 22, Iss. 12, 2005-01 ,pp. : 1061-1069

Adis International

Access to resources Recommend Favorite